
|Articles|July 1, 2003
Cancer Drug Reimbursement Facing Possible Reform
As Congress moves toward possible approval of a new prescription drug program for Medicare recipients later this summer, how payments for cancer drugs and therapeutic services are determined may well hang in the balance.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma
5











